Alnylam Pharmaceuticals: Cutting-Edge Pharma Stock Still Feels A Little Overvalued

Alnylam Pharmaceuticals, Inc. is rated a Hold due to intense ATTR-CM competition and pipeline execution risks. Read more on ...